Atorvastatin-Calcium-Trihydrat (Ph.Eur.) shortage — DE supply status & alternatives

Atorvastatin-Calcium-Trihydrat (Ph.Eur.)

ATC C10AA05

In supply · Australia

Atorvastatin Basics

In supply · 🇦🇺 Australia · short in🇩🇪 DE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names
Active ingredient (INN)	Atorvastatin-Calcium-Trihydrat (Ph.Eur.)

ATC level 5	C10AA05

ATC level 4	C10AA

Therapeutic category	Auto-created by Bundesinstitut für Arzneimittel und Medizinprodukte — Lieferengpässe scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇩🇪 22 June 2026

high reported

🇩🇪 28 Apr 2026

high reported

🇩🇪 5 Mar 2026

medium reported

🇩🇪 12 Feb 2026

medium reported

🇩🇪 4 Aug 2025

medium reported

🇩🇪 13 June 2025

medium reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.